louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07004660: Performances of Large Language Models in Kidney Allograft Diagnostics
Official title: Performances of Large Language Models in Kidney Allograft Diagnostics
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Transplantation
Keywords: Large language model
Banff classification
Diagnosis
Kidney transplantation
Biopsy
Lead sponsor: Paris Translational Research Center for Organ Transplantation
Sponsor class: OTHER
First posted: 2025-06-04
Enrollment: 240
Sex: ALL
Minimum age (years): 0
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Kidney recipients

Brief summary: Kidney allograft rejection diagnosis relies on the complex Banff classification, but its application is limited by variability and workload. Our group previously built a scripted automation system, though it required major expert input. This study assesses whether modern LLMs can achieve similar diagnostic performance using Banff-based prompts, without extensive manual engineering.

Detailed description: Kidney allograft rejection remains a leading cause of allograft failure. Histological diagnosis relies on the Banff classification, a complex and evolving rule based framework. While successive Banff working groups refined the guidelines over time, daily interpretation is still hampered by inter and intra pathologist variability and growing demands on renal pathologists. This is why our group previously built a fully scripted Banff automation system. However, this system demanded years of expert curation and bespoke code before reaching acceptable accuracy. Whether modern LLMs, which show high capabilities to generate consistent and transparent reasoning at scale, can match expert pathologists without such resource intensive engineering remains unknown. The present study was therefore designed to benchmark state of the art LLMs against consensus diagnoses from senior renal pathologists on a representative series of kidney allograft biopsies, and to explore whether properly engineered prompts can translate Banff rules into reliable, reproducible diagnostic output.

Eligibility criteria: Inclusion Criteria:

* Kidney recipients

Exclusion Criteria:

* Combined transplant

Primary outcomes:
measure: Biopsy diagnosis
timeFrame: The biopsy will be protocol biopsies performed at 3 months and 1 year post transplant, or for-cause biopsies performed at any time post transplant.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05993260: Using Text Messages to Boost COVID-19 Vaccine Booking Rate
Official title: Using Text Messages to Boost COVID-19 Vaccination Appointment Booking and Vaccination Rates: A Randomised Controlled Field Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vaccination Hesitancy
COVID-19
Lead sponsor: The Behavioural Insights Team
Sponsor class: OTHER
Collaborators: name: Public Health England
name: Department of Health and Social Care
name: NHS England
First posted: 2023-08-15
Enrollment: 1825937
Sex: ALL
Minimum age (years): 40
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is a nationwide randomised controlled trial (RCT) to test the impact of behavioural science-informed text messages notifying patients of their eligibility for the COVID-19 vaccine on vaccination rates.


Eligibility criteria: Inclusion Criteria:

* (i) satisfying the age criteria as defined above;
* (ii) recorded in the National Immunisation Management System (NIMS);
* (iii) with a valid mobile phone number;
* (iv) who had not already received or been invited for the COVID-19 vaccine via NIMS at the time of the study.

Exclusion Criteria:

* Participants with invalid phone numbers

Primary outcomes:
measure: Booking rate within 72 hours
timeFrame: 72 hours
Secondary outcomes:
measure: Vaccination rate within 14 days
timeFrame: 14 days
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: NHS England
Study officials:
affiliation: The Behavioural Insights Team
name: Hannah Behrendt, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01341860: Investigation of Genetic Marker Associated With Obesity in Koreans
Official title: Investigation of Genetic Marker Associated With Obesity in Koreans, A Single-nucleotide Polymorphism(SNP) Analysis for Korean Obese
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Obesity
Lead sponsor: Kyunghee University Medical Center
Sponsor class: OTHER
First posted: 2011-04-26
Enrollment: 260
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: obese patients with BMI 25\~30 kg/m2 who visited Kyung Hee University Hospital, Seoul, Korea

Brief summary: A single-nucleotide polymorphism (SNP) analysis of DNA obtained from peripheral blood of the obese patients and the normal control will be performed to find genetic marker for obesity


Eligibility criteria: Inclusion Criteria:

* BMI 25\~30kg/m2

Exclusion Criteria:

* All were nonsmokers and had no evidence of cancer, liver, renal, hematological disease or other metabolic disorders other than obesity

Primary outcomes:
measure: genotyping for the SNP associated with BMI
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Kyunghee University
name: Jae-Young Um, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00481260: Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous
Official title: Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hgb C Hemoglobinopathy
Keywords: Hgb C
Screening
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2007-06-01
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed at the pediatric Hematology Unit of laboratory data from the thalassemia screening in northern Israel

Brief summary: Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups.

Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent.

Detailed description: Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups.

Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent.

The study will record the clinical characteristics of the homozygous Hgb C patients and the hematology characteristics of all the heterozygous carriers detected in northern Israel

Eligibility criteria: Inclusion Criteria:

* All patients diagnosed as homozygous for Hgb C disease or double heterozygous in combination to other abnormal hemoglobin, and all the carriers detected in the hematology laboratory during the screening for abnormal hemoglobins in northern Israel

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Pediatric Hematology Unit - HaEmek Medical Center
Study officials:
affiliation: Pediatric Hematology Unit, Ha'Emek Medical Center
name: Ariel Koren, MD
role: STUDY_DIRECTOR
affiliation: Hematology Laboratory - HaeEmek Medical Center
name: luci Zalman, Phd
role: STUDY_CHAIR
References:
Clinical trial NCT00771160: MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)
Official title: MK0476 Phase III Long-term Study -Perennial Allergic Rhinitis-
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Rhinitis, Allergic
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2008-10-13
Enrollment: 120
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A clinical study evaluates the efficacy and safety of MK0476 in adult patients with Perennial Allergic rhinitis.


Eligibility criteria: Inclusion Criteria:

* Adult Patients With Perennial Allergic Rhinitis

Exclusion Criteria:

* Patients Who Have Nasal Diseases (E.G., Nasal Polyp, Septonasal Arcuation, Hypertrophic Rhinitis), Upper Respiratory Infection, Sinusitis, Infectious Rhinitis And Those Disease Severe Enough To Interfere With Assessment Of Effectiveness
* Patients Who Have Rhinitis Medicamentosa, Or Nonallergic Rhinitis (E.G., Vasomotor Rhinitis, Eosinophilia Rhinitis)
* Patient Has A Disease Of The Cardiovascular, Hepatic, Renal, Hematologic Systems, Or Other Severe Disease

Primary outcomes:
measure: Any clinical or laboratory adverse experience
timeFrame: 12 weeks
Secondary outcomes:
measure: The daily mean of the composite nasal symptoms score at each of biweekly visits during the treatment period (average over the previous 2 weeks) or at time of termination
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04780360: Cyanoacrylate Tissue Adhesives Versus Silk Suture at the Palatal Donor Site of Sub Epithelial Connective Tissue Graft
Official title: Evaluation of Post Operative Pain, Early Wound Healing, and the Time of Application of Cyanoacrylates Tissue Adhesives Versus Silk Sutures at the Palatal Donor Area of Subepithelial Connective Tissue Grafts (CTG) A Randomized Clinical Trial: Comparative Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: The Effect of Local Aplication of Cayanoacrylate Tissue Adhesives on Improving the Healing
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-03-03
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Subepithelial connective tissue grafts (CTG) are considered the gold standard procedure with proven clinical success when it comes to gingival augmentation aims to to improve periodontal health, which can enhance the long-term prognosis of teeth by obtaining soft tissue coverage of exposed root surfaces and/or augmentation the dimensions of gingival tissue. The procedure require harvesting tissue from a the palate, which increases the complexity of the procedure and patient discomfort. Complications after harvesting a graft would be pain, inflammation, bleeding, flap necrosis and infection in the donor site.


Eligibility criteria: Inclusion Criteria:

* Patients with mucogingival defects scheduled for sub epithelial connective tissue graft
* Age at least 18 years.
* Not having any systemic disease that could compromise wound healing
* No periodontal surgery on the experimental sites.
* No smoking,
* No pregnancy or lactation

Exclusion Criteria:

* Patients with coagulation disorders
* patients on corticosteroids, with uncontrolled diabetes, or with any systemic disease that precluded periodontal surgery
* patients with a history of contact dermatitis to formaldehyde
* Loss of maxillary premolars and molars
* Medications or antibiotics used in the previous 6 months
* Pregnancy or lactation
* Smoking

Primary outcomes:
measure: Early Wound Healing
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry, Cairo Universty
Study officials:
References:
Clinical trial NCT00851760: Epiretinal Macular Membrane and Cataract Extraction
Official title: Idiopathic Epiretinal Macular Membrane and Cataract Extraction : Combined vs Consecutive Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Epiretinal Macular Membrane
Cataract Extraction
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2009-02-26
Enrollment: 174
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators proposed to assess the functional and anatomical outcomes of cataract and idiopathic epiretinal macular membrane extraction in combined and consecutive surgeries.

Detailed description: A retrospective nonrandomized clinical case series study collected 174 consecutive eyes of 174 patients undergoing macular surgery between January 2005 and December 2006. Patients suffering from epiretinal macular membranes (ERM) secondary to uveitis, trauma, or associated with a simultaneous retinal detachment (RD) were excluded. We treated 109 eyes with a combined procedure (group 1) and 65 eyes with a consecutive surgery (membrane surgery and cataract separately)(group 2).

Eligibility criteria: Inclusion Criteria:

* All patients had symptomatic visual loss and needed vitrectomy for ERM removal.

Exclusion Criteria:

* Patients suffering from ERM secondary to uveitis, trauma, or associated with a simultaneous RD were excluded.

Primary outcomes:
measure: Combined and consecutive surgeries are effective procedures to treat idiopathic ERM. The functional and anatomical results are equivalent in both procedures.
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: Ophthalmology Unit CHU Dijon
state: Burgundy
Study officials:
References:
Clinical trial NCT01002560: The Identification of Novel Prognostic Markers in Melanoma
Official title: Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Malignant Melanoma
Keywords: Melanoma
Novel Prognostic Markers
Lead sponsor: Royal Marsden NHS Foundation Trust
Sponsor class: OTHER
First posted: 2009-10-27
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital

Brief summary: The purpose of this project is to analyze tumour tissue from a group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital.

Detailed description: Background - The Royal Marsden Hospital and the Institute of Cancer Research constitute the largest comprehensive cancer centre in Europe. In addition to an in-house drug development program, phase I - phase III clinical trials of novel anti-cancer agents are hosted. In order to investigate the optimal use of novel molecularly targeted agents, access to clinical tumour samples is needed in order to determine which particular cancer type expresses a molecular "signature" that may indicate potential therapeutic utility. Understanding such signatures should accelerate the registration of new drugs for routine cancer therapy; offering the potential of selecting those patients with tumour types most likely to benefit from therapy. Furthermore, new insights into disease biology may be gained.

Main research question/ objective - Are there features of primary melanoma or lymph node metastases that predict subsequent clinical outcome better than existing markers?

Eligibility criteria: Inclusion Criteria:

* Diagnosis of melanoma
* Adequate paraffin-embedded material available for analysis.
* Adequate clinical follow-up information
* Written informed consent where applicable

Exclusion Criteria:

* Inadequate paraffin-embedded material available
* Inadequate clinical follow-up information.

Primary outcomes:
measure: Given that the nature of the research is qualitative, there is no primary outcome measure.
Secondary outcomes:
Other outcomes:
Locations:
city: Sutton
country: United Kingdom
facility: Royal Marsden NHS Foundation Trust
state: Surrey
Study officials:
affiliation: Royal Marsden NHS Foundation Trust
name: Professor Martin Gore
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01399476: Endoscopic Myotomy of the Lower Esophageal Sphincter for Achalasia
Official title: Endoscopic Submucosal Tunnel Dissection for Endoluminal Partial Myotomy of the Lower Esophageal Sphincter for Achalasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Achalasia
Keywords: Achalasia
Lead sponsor: The Oregon Clinic
Sponsor class: OTHER
First posted: 2011-07-21
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a study of the safety and efficacy of a new surgical procedure using endoscopic instruments and a tunneling technique to reach the LES for dissection. We hypothesize that this technique provides an incisionless, less invasive option with similar functional outcome compared to standard Heller myotomy.

Detailed description: By the endoscopic creation of an esophageal submucosal tunnel the inner circular muscle layer can be easily visualized. In contrast to conventional Heller myotomy, the dissection of only the inner circular esophageal muscle layer leaves the outer longitudinal muscle layer intact. Thereby, post-interventional reflux disease should be avoided.

Eligibility criteria: Inclusion Criteria:

* Ability to undergo general anesthesia
* Age \> 18 yrs. of age and \< 85 yrs. of age
* Ability to give informed consent
* Candidate for elective Heller myotomy

Exclusion Criteria:

* Previous mediastinal or esophageal surgery
* Contraindications for esophagogastroduodenoscopy
* BMI \> 45

Primary outcomes:
measure: Improved quality of life as defined by survey pre and post surgery
timeFrame: six months
Secondary outcomes:
measure: Negative pH test
timeFrame: six months
measure: Bleeding
timeFrame: 1 year
Other outcomes:
Locations:
city: Portland
country: United States
facility: The Oregon Clinic
state: Oregon
Study officials:
affiliation: The Oregon Clinic
name: Lee L Swanstrom, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kurian AA, Dunst CM, Sharata A, Bhayani NH, Reavis KM, Swanstrom LL. Peroral endoscopic esophageal myotomy: defining the learning curve. Gastrointest Endosc. 2013 May;77(5):719-25. doi: 10.1016/j.gie.2012.12.006. Epub 2013 Feb 5.
Clinical trial NCT03021876: L-carnitine Corrects Ammonia Metabolism in Hepatectomized Patients
Official title: L-carnitine Corrects Ammonia Metabolism in Hepatectomized Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Ammonia Metabolism
Lead sponsor: Kochi University
Sponsor class: OTHER
First posted: 2017-01-16
Enrollment: 80
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: L-carnitine is synthesized from lysine and methionine. Postmortem concentrations of carnitine in liver, muscle, heart, kidney, and brain averaged only one-fourth to one-third those in corresponding tissues of eight normally nourished non-hepatic patients who died after an acute illness of a 1-3-day duration. In the recent years, it has been reported that sirtuin 3 (SIRT3) is protective against acute kidney injury (AKI) and suggest that enhancing SIRT3 to improve mitochondrial dynamics has potential as a strategy for improving outcomes of renal injury. In the current study, it is the first clinical interventional research whether L-carnitine corrects ammonia metabolism associated with liver injury in hepatectomized patients.


Eligibility criteria: Inclusion Criteria:

* patients were those surgically treated for hepato-biliary diseases

Exclusion Criteria:

* Patient exclusion criteria included a body weight loss greater than 10% during the six months prior to surgery, the presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal or heart disease.

Primary outcomes:
measure: postoperative ammonia levels
timeFrame: 3 points; preoperative baseline, postoperative day 1, and day3
Secondary outcomes:
measure: length of hospitalization after liver resection
timeFrame: up to 24 weeks
Other outcomes:
Locations:
city: Kochi
country: Japan
facility: Kochi Health Sciences Center
Study officials:
References:
citation: Okabayashi T, Sui K, Mastumoto T, Iwata J, Morita S, Iiyama T, Shimada Y. l-Carnitine Improves Postoperative Liver Function in Hepatectomized Patients. JPEN J Parenter Enteral Nutr. 2020 Jul;44(5):823-830. doi: 10.1002/jpen.1720. Epub 2019 Oct 9.